Asha Kigozi

Biochemistry, Genetics and Molecular Biology · Life Sciences

3h-index236citations43works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chromatin Remodeling and Cancer(31), Cancer Mechanisms and Therapy(25), Animal Virus Infections Studies(17), Ovarian cancer diagnosis and treatment(10), Cancer, Hypoxia, and Metabolism(8)

Publications43 total

Supplementary Table 12 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 6 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 4 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 7 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 10 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 8 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 2 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 8 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Data from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 1 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 3 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 9 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 11 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 5 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Figure legends and methods from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Figure legends and methods from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Figures from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Figures from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 11 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
Supplementary Table 12 from Synthetic Lethal Targeting of <i>ARID1A</i>-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Ilirjana Bajrami(43), Alan Ashworth(43), Rachel Brough(32), Rowan Miller(31), Chris T. Williamson(31), Simon S. McDade(31), Rumana Rafiq(31), Helen N. Pemberton(31), Rachael Natrajan(31), Josephine Joel(31), Holly Astley(31), Claire Mahoney(31), Chris Torrance(31), John D. Gordan(31), James T. Webber(31), Rebecca S. Levin(31), Kevan M. Shokat(31), Sourav Bandyopadhyay(31), James Campbell(30), Christopher J. Lord(27)